US 11685721
Human plasma kallikrein inhibitors
granted A61PA61P1/02A61P1/04
Quick answer
US patent 11685721 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 33
- CPC classes
- A61P, A61P1/02, A61P1/04, A61P11/04, A61P13/02